There are few options for treating painful bone metastasis in multiple sites. Hemibody irradiation, although effective, is limited due to the serious hematologic toxicity. Therefore, use of radiophamaceuticals has been attemyted particularly for the osteoblastic bone metastasis. Strontium-89 (Sr-89) ia a pure beta emitter with its energy 1.4 MeV. It follows the biochemical pathways of calcium and selectively concentrates at the metastatic bone sites with minimai hematologic toxicity. From l993 to 1994, Sr-89 treatment has been performed in 8 patients with painful bone metastaeis from either prostate (6 patients) or breast cancers (2 patients) The patients had the initial level of WBC 3000/L, platelets 100,000/L, and normal renal function. Four mCi(l48 MBq) of Sr-89 was intravenously iniected and the patients were regularly followed with blood cell count test, simple bone x-ray, and radioisotpe bone scan. The changes of subjective pain were scored in 6 patients until the time of this report. Excellent pain relief was achieved in all except 1 patient, who died 1 month after Sr-89 treatment due to advanced disease. Accordingly, the amount of the analgesics intake by the patients showed corresponding decrease. There was slight decrease in the level of WBCs and plateletes at 2-6 weeks after Sr-89 treetment, however those soon recovered with conservative management. Above results show that the Sr-89 treatment can provide effective palliation in petients with painful bone metastasis with acceptable toxicity. However, further study is urgent to establish its indication, timinh and combination with local radiotherapy.
PDF Links
Full text via DOI 
Download Citation 
